New findings suggest semaglutide's benefits may extend well beyond diabetes and weight loss and into airway disease and mood disorders.
News|Articles|October 21, 2024
Q&A: What Pharmacists Need to Know about Onyda XR for the Treatment of ADHD
Author(s)Killian Meara
A conversation with Rakesh Jain, MD, MPH, clinical professor in the Department of Psychiatry at Texas Tech University School of Medicine.
Advertisement
Advertisement
Clonidine hydrochloride (Onyda XR) was approved by the FDA in May 2024 for the treatment of ADHD in pediatric patients 6 years of age and older. The medication, which is now available in the United States, is a once-daily, extended release, oral suspension medication and is the first liquid, non-stimulant for ADHD approved in the country.
Related to this article
Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.
The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.
A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.
A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.
Community pharmacists offer accessible care, improve medication adherence, and build trust through education, vaccination support, and local health leadership.
Advertisement
Advertisement